| Basics |
Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.
|
| IPO Date: |
August 16, 1995 |
| Sector: |
Healthcare |
| Industry: |
Health Care Equipment and Supplies |
| Market Cap: |
$1.03B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.54 | 1.28%
|
| Avg Daily Range (30 D): |
$0.32 | 2.45%
|
| Avg Daily Range (90 D): |
$0.37 | 2.65%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.34M |
| Avg Daily Volume (30 D): |
.89M |
| Avg Daily Volume (90 D): |
.98M |
| Trade Size |
| Avg Trade Size (Sh.): |
84 |
| Avg Trade Size (Sh.) (30 D): |
64 |
| Avg Trade Size (Sh.) (90 D): |
74 |
| Institutional Trades |
| Total Inst.Trades: |
9,598 |
| Avg Inst. Trade: |
$2.12M |
| Avg Inst. Trade (30 D): |
$1.76M |
| Avg Inst. Trade (90 D): |
$1.92M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.99M |
| Avg Closing Trade (30 D): |
$2.14M |
| Avg Closing Trade (90 D): |
$2.21M |
| Avg Closing Volume: |
75.85K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-6.46
|
$-.07
|
$-6.31
|
|
Diluted EPS
|
$-6.46
|
$-.07
|
$-6.31
|
|
Revenue
|
$ 1.64B
|
$ 402.06M
|
$ 415.61M
|
|
Gross Profit
|
$ 859.83M
|
$ 206.99M
|
$ 209.33M
|
|
Net Income / Loss
|
$ -495.34M
|
$ -5.4M
|
$ -484.07M
|
|
Operating Income / Loss
|
$ -480.78M
|
$ 11.76M
|
$ -512.67M
|
|
Cost of Revenue
|
$ 783.14M
|
$ 195.07M
|
$ 206.27M
|
|
Net Cash Flow
|
$ 17.03M
|
$ 14.27M
|
$ -21.19M
|
|
PE Ratio
|
|
|
|
|
|
|
